Hepion Pharmaceuticals Inc (HEPA) concluded trading on Wednesday at a closing price of $0.17, with 5.77 million shares of worth about $0.98 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -73.39% during that period and on February 19, 2025 the price saw a loss of about -3.72%. Currently the company’s common shares owned by public are about 10.62M shares, out of which, 10.57M shares are available for trading.
Stock saw a price change of -12.81% in past 5 days and over the past one month there was a price change of -63.01%. Year-to-date (YTD), HEPA shares are showing a performance of -63.09% which decreased to -93.57% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.12 but also hit the highest price of $3.33 during that period. The average intraday trading volume for Hepion Pharmaceuticals Inc shares is 19.84 million. The stock is currently trading -3.48% below its 20-day simple moving average (SMA20), while that difference is down -55.42% for SMA50 and it goes to -76.51% lower than SMA200.
Hepion Pharmaceuticals Inc (NASDAQ: HEPA) currently have 10.62M outstanding shares and institutions hold larger chunk of about 14.69% of that.
The stock has a current market capitalization of $1.84M and its 3Y-monthly beta is at 1.59. It has posted earnings per share of -$4.39 in the same period. It has Quick Ratio of 1.30. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HEPA, volatility over the week remained 14.16% while standing at 22.87% over the month.
Analysts are in expectations that Hepion Pharmaceuticals Inc (HEPA) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by ROTH Capital on July 20, 2020 offering a Buy rating for the stock and assigned a target price of $14 to it.
